Investigation Launched by Pomerantz Law Firm Regarding Rafael Holdings, Inc.

Pomerantz Law Firm Investigates Rafael Holdings, Inc.

In a significant development for investors, the Pomerantz Law Firm has announced an investigation into claims related to Rafael Holdings, Inc. (NYSE: RFL). The firm's inquiry primarily focuses on whether Rafael, alongside specific officers and/or directors, may have engaged in securities fraud or pursued illegitimate business practices.

On September 30, 2026, Rafael issued a press release detailing the efficacy and safety results from its Cyclo Therapeutics, LLC subsidiary's pivotal Phase 3 study, TransportNPC™. This trial assessed the drug Trappsol® Cyclo™, an intravenous treatment for the rare Niemann-Pick Disease Type C (NPC). Pomerantz points out that the trial's findings did not meet the statistical significance required for its primary endpoint, an outcome that has resulted in considerable investor concern.

This announcement had a dramatic impact on the company’s stock, which plummeted by $0.71 per share, a staggering 34.98% decrease, leading to a closing price of $1.32 per share that day. The rapid decline in stock price highlights the market's sensitive reaction to clinical trial outcomes, particularly in the biotech sector, where results can dramatically affect investor sentiment and company valuation.

Pomerantz LLP, known for its expertise in corporate, securities, and antitrust class litigation, encourages investors in Rafael Holdings to connect with attorney Danielle Peyton for further information, especially if they're interested in joining the class action. The firm, with a history dating back over 85 years, has built a reputation for fighting on behalf of those affected by securities fraud and corporate misconduct. With offices across several major cities worldwide, including New York, Chicago, London, and Tel Aviv, they are strategically positioned to handle such significant legal claims.

As the investigation unfolds, it remains crucial for affected investors to stay informed regarding the actions Pomerantz may initiate and to consider the potential implications on their investments. The outcome of this inquiry could not only influence the future direction of Rafael Holdings but might also set a precedent in how similar cases are approached in the industry.

For investors seeking to understand their legal standings or exploring their options, reaching out to Pomerantz LLP is highly advisable—given their robust track record in securing favorable outcomes for investors wronged by deceptive practices.

Contact Information:
Danielle Peyton
Pomerantz LLP
Email: [email protected]
Phone: 646-581-9980 ext. 7980

This report sheds light on the importance of transparency and accountability in the corporate sector, particularly for investors in high-stakes fields like biotechnology. As the legal proceedings advance, it will be essential for all stakeholders to remain engaged and proactive.